Skip to main content
VVT MED INC. logo

VVT MED INC. — Investor Relations & Filings

Ticker · VVTM ISIN · CA91841T1084 TSXV Manufacturing
Open in API
Filings indexed 362 across all filing types
Latest filing 2025-03-31 Audit Report / Informat…
Country CA Canada
Listing TSXV VVTM

About VVT MED INC.

https://www.vvtmed.com/

VVT MED INC. develops, manufactures, and commercializes minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for the treatment of varicose veins and chronic venous disorders. The company's technology centers on the ScleroSafe Platform, a patented delivery system for Endovenous Chemical Ablation (ECA). ScleroSafe is designed to simplify procedures, shorten treatment times, and minimize patient recovery compared to traditional surgical and ablation methods. Products like ScleroSafe and V-Block, which treats severely dilated Great Saphenous Vein conditions, offer enhanced safety and efficacy. The platform holds regulatory clearances including FDA 510(k) and CE approval.

Recent filings

Filing Released Lang Actions
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 92% confidence The document begins with the Independent Auditor’s Report from Davidson & Company LLP and contains the audited consolidated financial statements and accompanying notes for DXI Capital Corp. It is a standalone audit opinion and set of financial statements (not the full annual report), fitting the definition for Audit Report / Information (AR). FY 2024
2025-03-31 English
Material change report - English.pdf
M&A Activity Classification · 85% confidence The document is a Canadian Form 51-102F3 Material Change Report disclosing conditional TSXV approval for a reverse takeover (“Proposed Transaction”). This is a statutory disclosure of an M&A transaction rather than a financial report or dividend notice. It best fits the M&A Activity category (TAR) for announcements related to takeover bids or merger proposals.
2025-03-28 English
News release - English.pdf
Regulatory Filings
2025-03-25 English
News release - English.pdf
M&A Activity Classification · 92% confidence The document is a news release titled “DXI Capital Corp. Provides Update on the Proposed Reverse Takeover [RTO] of V.V.T. Med Ltd. and Exiteam Acquisition Corp.” It discusses the status of a merger/acquisition transaction, submission of filing statements to the exchange, and expected closing of the RTO. There is no detailed financial report, nor is it an earnings release or regulatory notice unrelated to M&A. This is clearly an announcement related to a merger/takeover process, fitting the M&A Activity category.
2024-11-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the Interim CEO of DXI Capital Corp. regarding the review and fair presentation of the interim financial report and interim MD&A for the period ending September 30, 2024. It is a Venture Issuer Basic Certificate under Form 52-109FV2, which is a regulatory certification related to interim filings. The document does not contain actual financial statements or substantive financial data but is an attestation of the interim filings' accuracy and completeness. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (3030 characters), and it is clearly a certification rather than the report or announcement of a report. Therefore, the correct classification is Regulatory Filings (RNS).
2024-11-22 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the CFO of DXI Capital Corp. regarding the review and fair presentation of the interim financial report and interim MD&A for the period ending September 30, 2024. It is a Form 52-109FV2, which is a certification of interim filings for a venture issuer. The document does not contain actual financial statements or substantive financial data but is an attestation of the accuracy and completeness of the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3039 characters), and it is clearly a certification letter rather than a full interim report.
2024-11-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.